免疫相关不良事件（irAEs）的发生可能与肿瘤患者中的检查点抑制剂（CPIs）的临床疗效相关。因此，我们调查了irAEs和预处理参数对大规模真实患者队列中的治疗结果的影响。我们在2011年至2018年期间接受CPIs治疗且一直随访到2021年的患者中进行了单中心、回顾性、观察性研究。主要结局是总生存率，次要结局是irAEs的发生情况。总共有229名患有不同肿瘤形态（41%非小细胞肺癌[NSCLC]，29%黑色素瘤）的患者接受282个CPI治疗过程（ipilimumab、nivolumab、pembrolizumab或atezolizumab）。34%的患者发生了irAEs（其中17%的CTCAE等级≥3）。 预处理CRP ≥ 10mg / L（风险比[HR] 2.064，p = 0.0003），Charlson并发症指数测量（HR 1.149，p = 0.014）和irAEs（HR 0.644，p = 0.036）（年龄调整，n = 216）是与死亡率独立相关的因素。基线嗜酸性粒细胞计数≤0.2 × 109 / L是进一步独立的死亡率预测因子（经过年龄，CRP，CCI和irAE调整的HR = 2.252，p = 0.002，n = 166）。抗CTLA-4的使用（p <0.001）和预处理CRP <10mg / L与irAE发生有独立关联（p = 0.037）。我们发现在跨越多种肿瘤形态和治疗方案的真实患者队列中，irAE与改善总体生存率存在独立关联。预处理并发症、CRP和嗜酸性粒细胞计数代表可能的标记物，可以预测治疗反应。©2023年该作者. 由John Wiley＆Sons Ltd出版的Cancer Medicine。

The development of immune-related adverse events (irAEs) may be associated with clinical efficacy of checkpoint inhibitors (CPIs) in patients with cancer. We therefore investigated the effect of irAEs and pre-treatment parameters on outcome in a large, real-life patient cohort.We performed a single-centre, retrospective, observational study including patients who received CPIs from 2011 to 2018 and followed until 2021. The primary outcome was overall survival, and the secondary outcome was the development of irAEs.In total, 229 patients with different tumour entities (41% non-small cell lung cancer [NSCLC], 29% melanoma) received a total of 282 CPI treatment courses (ipilimumab, nivolumab, pembrolizumab or atezolizumab). Thirty-four percent of patients developed irAEs (of these 17% had CTCAE Grade ≥3). Factors independently associated with mortality were pre-treatment CRP ≥10 mg/L (hazard ratio [HR] 2.064, p = 0.0003), comorbidity measured by Charlson comorbidity index (HR 1.149, p = 0.014) and irAEs (HR 0.644, p = 0.036) (age-adjusted, n = 216). Baseline eosinophil count ≤0.2 × 109 /L was a further independent predictor of mortality (age-, CRP-, CCI- and irAE-adjusted HR = 2.252, p = 0.002, n = 166). Anti-CTLA-4 use (p < 0.001), and pre-treatment CRP <10 mg/L were independently associated with irAE occurrence (p = 0.037).We found an independent association between irAE occurrence and improved overall survival in a real-life cohort spanning multiple tumour entities and treatment regimens. Pre-treatment comorbidities, CRP and eosinophil count represent potential markers for predicting treatment response.© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.